Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a wearable sensor beat Finger-Prick tests for type 2 diabetes?

NCT ID NCT06587438

Disease control Sponsor: Sinocare Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial asks whether real-time continuous glucose monitoring (CGM) can improve blood sugar control in adults with type 2 diabetes who do not use insulin. Participants will either use a CGM device or stick to standard self-monitoring with a blood glucose meter. The study tracks changes in HbA1c, a key marker of long-term blood sugar levels, over 24 weeks. If CGM proves beneficial, it could offer a more convenient and effective way to manage diabetes without insulin.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Real-time continuous glucose monitoring (CGM) device
What this could lead to
If effective, this could support wider use of CGM for people with type 2 diabetes who do not take insulin, potentially improving blood sugar control and reducing complications.
What could go wrong
The trial is relatively small and early, and results may not apply to all patients. CGM devices can be costly and may not be accessible to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

160 people

The number who actually took part.

Started

Jan 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (1)Subjects aged ≥18 years at screening (based on the day of signing the informed consent form) and of any gender * (2)Patients diagnosed with type 2 diabetes * (3)Prior to the screening, glycemic control was suboptimal with diet, exercise control, and oral medication or glucagon-like peptide-1RA (GLP-1RA) therapy maintained for more than 3 months, 7.5%≤HbA1c≤10% * (4)Subjects voluntarily sign an informed consent form Exclusion Criteria: * (1)Patients treated with insulin within 3 months prior to screening * (2)Currently or have used a CGM device within 3 months prior to enrollment * (3)Serious skin disease at the sensor placement site, allergy to tape or adhesives * (4)Pregnant females, those with a positive pregnancy test result at screening, or those who plan to become pregnant during the study * (5)Those who are participating or will participate in other clinical trials * (6)Those who, in the opinion of the investigator, should not participate in this clinical trial, such as: ①those who have a history of eye trauma or other diagnosed eye diseases resulting in visual impairment, etc.; ②those who are unwilling or unable to fully understand or cooperate due to speech disorders; ③those who suffer from mental disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus

Contacts and locations

Locations

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, 250012, China

  • Renmin Hospital of Wuhan University （Hubei General Hospital）

    Wuhan, Hubei, 430060, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, 200233, China

  • The Eighth Affiliated Hospital of Southern Medical University

    Shunde, Guangdong, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.